An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron
Baoxue Quan(Sichuan University), Shengyong Yang(Sichuan University), Renjie Zhou(Sichuan University), Chaemin Yoon(University of Hong Kong), Mingxin Chen(Sichuan University), Huiping Shuai(University of Hong Kong), Hin Chu(Hong Kong Science and Technology Parks Corporation), Jasper Fuk‐Woo Chan(University of Hong Kong), Ming Wu(Xuzhou Medical College), Anjie Xia(Sichuan University), Yuxin Hou(University of Hong Kong), Jian Lei(Sichuan University), Falu Wang(Sichuan University), Guifeng Lin(Sichuan University), Kwok‐Yung Yuen(University of Hong Kong - Shenzhen Hospital), Yifei Wang(Southwest Medical University), Weimin Li(Sichuan University), Shiyu Zhang(Sichuan University), Kai Wang(Sichuan University), Xinlei Liu(Guiyang Medical University), Chong Huang(Sichuan University), Wei Yang(Sichuan University), Rui Zeng(Sichuan University), Chenyu Tian(Sichuan University), Jingxin Qiao(Sichuan University), Terrence Tsz‐Tai Yuen(Sichuan University), Wenpei Li(Sichuan University)
Cited by 101
Related Papers
Coronaviruses — drug discovery and therapeutic options
|Nature Reviews Drug Discovery|2016|1.8k
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
|Signal Transduction and Targeted Therapy|2021|1.6k
Severe acute respiratory syndrome
|Nature Medicine|2004|1.2k
Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050
|JAMA Oncology|2023|822
Infection of bat and human intestinal organoids by SARS-CoV-2
|Nature Medicine|2020|547